Celldex Therapeutics, Inc Technographics

Discover the latest software purchases and digital transformation initiatives being undertaken by Celldex Therapeutics, Inc and its business and technology executives. Each quarter our research team identifies on-prem and cloud applications that are being used by the 132 Celldex Therapeutics, Inc employees from the public (Press Releases, Customer References, Testimonials, Case Studies and Success Stories) and proprietary sources.

During our research, we have identified that Celldex Therapeutics, Inc has purchased the following applications: iCIMS Recruit Applicant Tracking System for Applicant Tracking System in 2013, Microsoft Azure Cloud Services for Application Hosting and Computing Services in 2015, Microsoft 365 for Collaboration in 2020 and the related IT decision-makers and key stakeholders.

Our database provides customer insight and contextual information on which enterprise applications and software systems Celldex Therapeutics, Inc is running and its propensity to invest more and deepen its relationship with iCIMS , Microsoft , DocuSign or identify new suppliers as part of their overall Digital and IT transformation projects to stay competitive, fend off threats from disruptive forces, or comply with internal mandates to improve overall enterprise efficiency.

We have been analyzing Celldex Therapeutics, Inc revenues, which have grown to $4.7 million in 2024, plus its IT budget and roadmap, cloud software purchases, aggregating massive amounts of data points that form the basis of our forecast assumptions for Celldex Therapeutics, Inc intention to invest in emerging technologies such as AI, Machine Learning, IoT, Blockchain, Autonomous Database or in cloud-based ERP, HCM, CRM, EPM, Procurement or Treasury applications.

Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. Celldex Therapeutics (NASDAQ: CLDX) was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases. The Company's pipeline is comprised of therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers, including many underserved or completely un-served orphan indications. This has created a leading pipeline in immuno-oncology.